학술논문
DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function.
Document Type
Article
Author
Madurka, Ildiko; Vishnevsky, Alexander; Soriano, Joan B.; Gans, Stephanus J.; Ore, Danilo Joel Salazar; Rendon, Adrian; Ulrik, Charlotte S.; Bhatnagar, Sushma; Krishnamurthy, Srikanth; Mc Harry, Kirsten; Welte, Tobias; Fernandez, Alberto A.; Mehes, Beata; Meiser, Karin; Gatlik, Ewa; Sommer, Ulrike; Junge, Guido; Rezende, Ederlon; Fernandez, Alberto Alfredo; Bagu, Ana Maria
Source
Infection; Jun2023, Vol. 51 Issue 3, p641-654, 14p, 1 Diagram, 2 Charts, 3 Graphs
Subject
Language
ISSN
03008126
Abstract
Copyright of Infection is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)